发明公开
EP1879584A1 PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME
有权
PYRIMIDYLAMINOBENZAMID衍生物对增多综合征
- 专利标题： PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME
- 专利标题（中）： PYRIMIDYLAMINOBENZAMID衍生物对增多综合征
-
申请号： EP06724677.7申请日： 2006-05-02
-
公开(公告)号： EP1879584A1公开(公告)日： 2008-01-23
- 发明人: MANLEY, Paul, W. , MESTAN, Jürgen , FABBRO, Doriano
- 申请人： Novartis AG , NOVARTIS-PHARMA GMBH
- 申请人地址： Lichtstrasse 35 4056 Basel CH
- 专利权人： Novartis AG,NOVARTIS-PHARMA GMBH
- 当前专利权人： Novartis AG,NOVARTIS-PHARMA GMBH
- 当前专利权人地址： Lichtstrasse 35 4056 Basel CH
- 代理机构： Crawley, Patrick Edward
- 优先权： US676751P 20050502
- 国际公布： WO2006117185 20061109
- 主分类号： A61K31/506
- IPC分类号： A61K31/506 ; A61P7/00 ; A61P35/02
摘要：
The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilc syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome, chronic eosinophilic leukemia and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIP1L1-PDGFRα, TEL-PDGFRβ or similar mutations that activate PDGFR.
公开/授权文献
信息查询
IPC分类:
